Technical Analysis for DXR - Daxor Corporation

Grade Last Price % Change Price Change
grade F 8.2 0.61% 0.05
DXR closed up 0.61 percent on Thursday, July 18, 2019, on 10 percent of normal volume.
0 Watchers
View Intraday Alerts Watchlist Portfolio

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Down Up
See historical DXR trend table...

Date Alert Name Type % Chg
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 0.00%
20 DMA Support Bullish 0.00%
Bollinger Band Squeeze Range Contraction 0.00%
Outside Day Range Expansion 0.00%
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 0.61%
Crossed Above 20 DMA Bullish 0.61%
Bollinger Band Squeeze Range Contraction 0.61%
Narrow Range Bar Range Contraction 0.61%
Gapped Up Strength 0.61%
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 4.19%

Older signals for DXR ...

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Get Started for Free!
Configure default chart indicators
Basic chart:
Profile
Daxor Corporation, a medical device manufacturing company, offers biotech services in the United States. The company develops and markets BVA-100 Blood Volume Analyzer, an instrument that measures human blood volume. BVA-100 Blood Volume Analyzer is used to diagnose and treat patients with heart failure, kidney failure, hypertension, and syncope; aid in fluid and blood transfusion management in the critical care unit; and aid in the diagnosis and treatment of disorders of red blood cell volume, including polycythemia and anemia, as well as used in pre-surgical evaluation of red blood cell volume. The company also provides cryobanking services, including blood and semen storage and related services. Daxor Corporation markets its products to hospitals and radiology imaging centers. The company was formerly known as Idant Corporation and changed its name to Daxor Corporation in May 1973. Daxor Corporation was founded in 1970 and is headquartered in New York, New York.
Medical Specialties Disorders Heart Failure Hypertension Blood Anemia Transfusion Medicine Hematology Science Blood Transfusion Kidney Failure Hematopathology Red Blood Cell Syncope
Is DXR a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Recent News
Date Title
Jun 18 Daxor Corporation Announces New Research Initiative with Leading Hospital in the Southeast and the BVA-100® Blood Volume Diagnostic Test
May 31 Daxor Corporation to Present at the LD Micro 9th Annual Invitational on June 4th, 2019
May 30 Daxor up 15% on new BVA-100 deal
May 30 MiMedx Group and BioCryst Pharmaceuticals among healthcare gainers; Amicus Therapeutics and ReWalk Robotics among losers
May 30 Daxor Corporation Announces New Partnership with Leading Hospital in North Carolina to Integrate the BVA-100® Blood Volume Analyzer Diagnostic Test as Part of Standard Clinical Practice
May 27 Our Take On Daxor Corporation's (NYSEMKT:DXR) CEO Salary
May 6 SBGI, AMG, GIII and ZNH among notable midday movers
May 6 ImmunoGen and Athenex among healthcare gainers; AAC Holdings and PetMed Express among losers
Mar 21 Daxor Corporation Addresses and Corrects Erroneous Seeking Alpha Healthcare News Editor Article of March 20, 2019
Mar 20 Daxor down 11% after corporate presentation
See more DXR news...
Indicators
Indicator Value
52 Week High 19.95
52 Week Low 4.3
Average Volume 8,951
200-Day Moving Average 10.0109
50-Day Moving Average 8.5676
20-Day Moving Average 8.0068
10-Day Moving Average 8.0349
Average True Range 0.4028
ADX 12.59
+DI 30.7417
-DI 23.8674
Chandelier Exit (Long, 3 ATRs ) 8.0758
Chandelier Exit (Short, 3 ATRs ) 8.3398
Upper Bollinger Band 8.5062
Lower Bollinger Band 7.5074
Percent B (%b) 0.69
BandWidth 12.474397
MACD Line -0.1618
MACD Signal Line -0.2208
MACD Histogram 0.059
Fundamentals Value
Market Cap 31.08 Million
Num Shares 3.79 Million
EPS -0.21
Price-to-Earnings (P/E) Ratio -39.05
Price-to-Sales 30.32
Price-to-Book 1.11
PEG Ratio 0.00
Dividend 0.03
Dividend Yield 0.37%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 8.55
Resistance 3 (R3) 8.51 8.36 8.49
Resistance 2 (R2) 8.36 8.27 8.37 8.47
Resistance 1 (R1) 8.28 8.21 8.32 8.32 8.45
Pivot Point 8.12 8.12 8.14 8.14 8.12
Support 1 (S1) 8.05 8.03 8.08 8.08 7.95
Support 2 (S2) 7.89 7.98 7.91 7.93
Support 3 (S3) 7.81 7.89 7.91
Support 4 (S4) 7.85